Tackling SARS-CoV-2: proposed targets and repurposed drugs
The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in February 2020, has currently infected more than 6 million people with fatalities near 371,000 and increasing exponentially, in absence of vaccines and drugs. The pathogenesis of SARS-CoV-2 is still being elucidated. Identif...
Gespeichert in:
| Veröffentlicht in: | Future medicinal chemistry 2020-09, Vol.12 (17), p.1579-1601 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1601 |
|---|---|
| container_issue | 17 |
| container_start_page | 1579 |
| container_title | Future medicinal chemistry |
| container_volume | 12 |
| creator | Joshi, Siddhi Joshi, Maithili Degani, Mariam S |
| description | The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in February 2020, has currently infected more than 6 million people with fatalities near 371,000 and increasing exponentially, in absence of vaccines and drugs. The pathogenesis of SARS-CoV-2 is still being elucidated. Identifying potential targets and repurposing drugs as therapeutic options is the need of the hour. In this review, we focus on potential druggable targets and suitable therapeutics, currently being explored in clinical trials, to treat SARS-CoV-2 infection. A brief understanding of the complex interactions of both viral as well as host targets, and the possible repurposed drug candidates are described with an emphasis on understanding the mechanisms at the molecular level. |
| doi_str_mv | 10.4155/fmc-2020-0147 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7307730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2514327844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-68656cb367590f95c64a6bedef470197635ae05756bfabb4bf4c64b6fcbf0a6a3</originalsourceid><addsrcrecordid>eNp1kN1LwzAUxYMobsw9-ioFn6NpPtc9CGP4BQPBTV9Dkia1c2tr0gr-92Z0Dn0wcElu8rsnhwPAeYquaMrYtdsaiBFGEKVUHIFhKhiHkwyL48M5zQZgHMIaxUXwJOPsFAwIZpxyTIZgulLmfVNWRbKcPS_hvH6FeJo0vm7qYPOkVb6wbUhUlSfeNp3vr3PfFeEMnDi1CXa830fg5e52NX-Ai6f7x_lsAQ3jpIV8whk3mnDBMuQyZjhVXNvcOipQmglOmLKIRbfaKa2pdjQimjujHVJckRG46XWbTm9tbmzVerWRjS-3yn_JWpXy70tVvsmi_pSCIBErClzuBXz90dnQynXd-Sp6lpillGAxoTRSsKeMr0Pw1h1-SJHcpS1j2nKXttylHfmL37YO9E-2Ech6wHVt520wpa2MlX0XJ0pTVvYf8W9UAI4m</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2514327844</pqid></control><display><type>article</type><title>Tackling SARS-CoV-2: proposed targets and repurposed drugs</title><source>MEDLINE</source><source>PubMed Central</source><creator>Joshi, Siddhi ; Joshi, Maithili ; Degani, Mariam S</creator><creatorcontrib>Joshi, Siddhi ; Joshi, Maithili ; Degani, Mariam S</creatorcontrib><description>The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in February 2020, has currently infected more than 6 million people with fatalities near 371,000 and increasing exponentially, in absence of vaccines and drugs. The pathogenesis of SARS-CoV-2 is still being elucidated. Identifying potential targets and repurposing drugs as therapeutic options is the need of the hour. In this review, we focus on potential druggable targets and suitable therapeutics, currently being explored in clinical trials, to treat SARS-CoV-2 infection. A brief understanding of the complex interactions of both viral as well as host targets, and the possible repurposed drug candidates are described with an emphasis on understanding the mechanisms at the molecular level.</description><identifier>ISSN: 1756-8919</identifier><identifier>EISSN: 1756-8927</identifier><identifier>DOI: 10.4155/fmc-2020-0147</identifier><identifier>PMID: 32564623</identifier><language>eng</language><publisher>England: Newlands Press Ltd</publisher><subject>Animals ; Antiviral Agents - therapeutic use ; antivirals ; Betacoronavirus - drug effects ; Betacoronavirus - growth & development ; Clinical trials ; Coronavirus Infections - drug therapy ; Coronaviruses ; COVID-19 ; Cytoplasm ; Disease transmission ; Drug development ; Drug Repositioning ; drug targets ; Drugs ; Endoplasmic reticulum ; Genomes ; Glycoproteins ; Humans ; Infections ; Membranes ; Pandemics ; Pneumonia, Viral - drug therapy ; Proteins ; Public health ; Receptors, Virus - drug effects ; repurposed drugs ; Review ; RNA polymerase ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; therapeutics ; Viruses</subject><ispartof>Future medicinal chemistry, 2020-09, Vol.12 (17), p.1579-1601</ispartof><rights>2020 Newlands Press</rights><rights>Copyright Newlands Press Sep 2020</rights><rights>2020 Newlands Press 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-68656cb367590f95c64a6bedef470197635ae05756bfabb4bf4c64b6fcbf0a6a3</citedby><cites>FETCH-LOGICAL-c563t-68656cb367590f95c64a6bedef470197635ae05756bfabb4bf4c64b6fcbf0a6a3</cites><orcidid>0000-0002-3455-2642 ; 0000-0001-7551-9948 ; 0000-0002-1871-4234</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307730/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307730/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32564623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joshi, Siddhi</creatorcontrib><creatorcontrib>Joshi, Maithili</creatorcontrib><creatorcontrib>Degani, Mariam S</creatorcontrib><title>Tackling SARS-CoV-2: proposed targets and repurposed drugs</title><title>Future medicinal chemistry</title><addtitle>Future Med Chem</addtitle><description>The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in February 2020, has currently infected more than 6 million people with fatalities near 371,000 and increasing exponentially, in absence of vaccines and drugs. The pathogenesis of SARS-CoV-2 is still being elucidated. Identifying potential targets and repurposing drugs as therapeutic options is the need of the hour. In this review, we focus on potential druggable targets and suitable therapeutics, currently being explored in clinical trials, to treat SARS-CoV-2 infection. A brief understanding of the complex interactions of both viral as well as host targets, and the possible repurposed drug candidates are described with an emphasis on understanding the mechanisms at the molecular level.</description><subject>Animals</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antivirals</subject><subject>Betacoronavirus - drug effects</subject><subject>Betacoronavirus - growth & development</subject><subject>Clinical trials</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytoplasm</subject><subject>Disease transmission</subject><subject>Drug development</subject><subject>Drug Repositioning</subject><subject>drug targets</subject><subject>Drugs</subject><subject>Endoplasmic reticulum</subject><subject>Genomes</subject><subject>Glycoproteins</subject><subject>Humans</subject><subject>Infections</subject><subject>Membranes</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Proteins</subject><subject>Public health</subject><subject>Receptors, Virus - drug effects</subject><subject>repurposed drugs</subject><subject>Review</subject><subject>RNA polymerase</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>therapeutics</subject><subject>Viruses</subject><issn>1756-8919</issn><issn>1756-8927</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kN1LwzAUxYMobsw9-ioFn6NpPtc9CGP4BQPBTV9Dkia1c2tr0gr-92Z0Dn0wcElu8rsnhwPAeYquaMrYtdsaiBFGEKVUHIFhKhiHkwyL48M5zQZgHMIaxUXwJOPsFAwIZpxyTIZgulLmfVNWRbKcPS_hvH6FeJo0vm7qYPOkVb6wbUhUlSfeNp3vr3PfFeEMnDi1CXa830fg5e52NX-Ai6f7x_lsAQ3jpIV8whk3mnDBMuQyZjhVXNvcOipQmglOmLKIRbfaKa2pdjQimjujHVJckRG46XWbTm9tbmzVerWRjS-3yn_JWpXy70tVvsmi_pSCIBErClzuBXz90dnQynXd-Sp6lpillGAxoTRSsKeMr0Pw1h1-SJHcpS1j2nKXttylHfmL37YO9E-2Ech6wHVt520wpa2MlX0XJ0pTVvYf8W9UAI4m</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Joshi, Siddhi</creator><creator>Joshi, Maithili</creator><creator>Degani, Mariam S</creator><general>Newlands Press Ltd</general><general>Newlands Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3455-2642</orcidid><orcidid>https://orcid.org/0000-0001-7551-9948</orcidid><orcidid>https://orcid.org/0000-0002-1871-4234</orcidid></search><sort><creationdate>20200901</creationdate><title>Tackling SARS-CoV-2: proposed targets and repurposed drugs</title><author>Joshi, Siddhi ; Joshi, Maithili ; Degani, Mariam S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-68656cb367590f95c64a6bedef470197635ae05756bfabb4bf4c64b6fcbf0a6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antivirals</topic><topic>Betacoronavirus - drug effects</topic><topic>Betacoronavirus - growth & development</topic><topic>Clinical trials</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytoplasm</topic><topic>Disease transmission</topic><topic>Drug development</topic><topic>Drug Repositioning</topic><topic>drug targets</topic><topic>Drugs</topic><topic>Endoplasmic reticulum</topic><topic>Genomes</topic><topic>Glycoproteins</topic><topic>Humans</topic><topic>Infections</topic><topic>Membranes</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Proteins</topic><topic>Public health</topic><topic>Receptors, Virus - drug effects</topic><topic>repurposed drugs</topic><topic>Review</topic><topic>RNA polymerase</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>therapeutics</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joshi, Siddhi</creatorcontrib><creatorcontrib>Joshi, Maithili</creatorcontrib><creatorcontrib>Degani, Mariam S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joshi, Siddhi</au><au>Joshi, Maithili</au><au>Degani, Mariam S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tackling SARS-CoV-2: proposed targets and repurposed drugs</atitle><jtitle>Future medicinal chemistry</jtitle><addtitle>Future Med Chem</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>12</volume><issue>17</issue><spage>1579</spage><epage>1601</epage><pages>1579-1601</pages><issn>1756-8919</issn><eissn>1756-8927</eissn><abstract>The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in February 2020, has currently infected more than 6 million people with fatalities near 371,000 and increasing exponentially, in absence of vaccines and drugs. The pathogenesis of SARS-CoV-2 is still being elucidated. Identifying potential targets and repurposing drugs as therapeutic options is the need of the hour. In this review, we focus on potential druggable targets and suitable therapeutics, currently being explored in clinical trials, to treat SARS-CoV-2 infection. A brief understanding of the complex interactions of both viral as well as host targets, and the possible repurposed drug candidates are described with an emphasis on understanding the mechanisms at the molecular level.</abstract><cop>England</cop><pub>Newlands Press Ltd</pub><pmid>32564623</pmid><doi>10.4155/fmc-2020-0147</doi><tpages>23</tpages><orcidid>https://orcid.org/0000-0002-3455-2642</orcidid><orcidid>https://orcid.org/0000-0001-7551-9948</orcidid><orcidid>https://orcid.org/0000-0002-1871-4234</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-8919 |
| ispartof | Future medicinal chemistry, 2020-09, Vol.12 (17), p.1579-1601 |
| issn | 1756-8919 1756-8927 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7307730 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Antiviral Agents - therapeutic use antivirals Betacoronavirus - drug effects Betacoronavirus - growth & development Clinical trials Coronavirus Infections - drug therapy Coronaviruses COVID-19 Cytoplasm Disease transmission Drug development Drug Repositioning drug targets Drugs Endoplasmic reticulum Genomes Glycoproteins Humans Infections Membranes Pandemics Pneumonia, Viral - drug therapy Proteins Public health Receptors, Virus - drug effects repurposed drugs Review RNA polymerase SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 therapeutics Viruses |
| title | Tackling SARS-CoV-2: proposed targets and repurposed drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T14%3A04%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tackling%20SARS-CoV-2:%20proposed%20targets%20and%20repurposed%20drugs&rft.jtitle=Future%20medicinal%20chemistry&rft.au=Joshi,%20Siddhi&rft.date=2020-09-01&rft.volume=12&rft.issue=17&rft.spage=1579&rft.epage=1601&rft.pages=1579-1601&rft.issn=1756-8919&rft.eissn=1756-8927&rft_id=info:doi/10.4155/fmc-2020-0147&rft_dat=%3Cproquest_pubme%3E2514327844%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2514327844&rft_id=info:pmid/32564623&rfr_iscdi=true |